The link of diabetes with co-occurring disorders in the brain involves complex and multifactorial pathways. Genetically engineered rodents that express familial Alzheimer's disease-associated mutant forms of amyloid precursor protein and presenilin 1 (PSEN1) genes provided invaluable insights into the mechanisms and consequences of amyloid deposition in the brain. Adding diabetes factors (obesity, insulin impairment) to these animal models to predict success in translation to clinic have proven useful at some extent only. Here, we focus on contributing factors to diabetic brain injury with the aim of identifying appropriate animal models that can be used to mechanistically dissect the pathophysiology of diabetes-associated cognitive dysfunction and how diabetes medications may influence the development and progression of cognitive decline in humans with diabetes.

Citations

Citations to this article as recorded by  

• The association between renal accumulation of pancreatic amyloid-forming amylin and renal hypoxia
  Nirmal Verma, Florin Despa
  Frontiers in Endocrinology.2023;[Epub]     CrossRef
• New insights toward molecular and nanotechnological approaches to antidiabetic agents for Alzheimer’s disease
  Sweta Priyadarshini Pradhan, Pratap Kumar Sahu, Anindita Behera
  Molecular and Cellular Biochemistry.2023; 478(12): 2739.     CrossRef
• Nicotinamide Prevents Diabetic Brain Inflammation via NAD+-Dependent Deacetylation Mechanisms
  Jeimy Katherine Torres-Méndez, Julia Niño-Narvión, Patricia Martinez-Santos, Elena María Goretti Diarte-Añazco, Karen Alejandra Méndez-Lara, Tania Vázquez del Olmo, Noemi Rotllan, Maria Teresa Julián, Núria Alonso, Didac Mauricio, Mercedes Camacho, Juan P
  Nutrients.2023; 15(14): 3083.     CrossRef
• Ipriflavone as a non‐steroidal glucocorticoid receptor antagonist ameliorates diabetic cognitive impairment in mice
  Ruifang Nie, Jian Lu, Rui Xu, Juanzhen Yang, Xingyi Shen, Xingnan Ouyang, Danyang Zhu, Yujie Huang, Tong Zhao, Xuejian Zhao, Yin Lu, Minyi Qian, Jiaying Wang, Xu Shen
  Aging Cell.2022;[Epub]     CrossRef
• Effects of linagliptin vs glimepiride on cognitive performance in type 2 diabetes: results of the randomised double-blind, active-controlled CAROLINA-COGNITION study
  Geert Jan Biessels, Chloë Verhagen, Jolien Janssen, Esther van den Berg, Gudrun Wallenstein, Bernard Zinman, Mark A. Espeland, Odd Erik Johansen
  Diabetologia.2021; 64(6): 1235.     CrossRef
• The Association Between Second-Line Oral Antihyperglycemic Medication on Types of Dementia in Type 2 Diabetes: A Nationwide Real-World Longitudinal Study
  Won Jun Kim, Jung Hyun Noh, Kyungdo Han, Cheol-Young Park
  Journal of Alzheimer's Disease.2021; 81(3): 1263.     CrossRef
• The role of traditional Chinese medicine in the treatment of cognitive dysfunction in type 2 diabetes
  Jinni Meng, Yafei Zhu, Huixia Ma, Xiaobo Wang, Qipeng Zhao
  Journal of Ethnopharmacology.2021; 280: 114464.     CrossRef
• Letter: Hypoglycemia and Dementia Risk in Older Patients with Type 2 Diabetes Mellitus: A Propensity-Score Matched Analysis of a Population-Based Cohort Study (Diabetes Metab J 2020;44:125–33)
  Jin Hwa Kim
  Diabetes & Metabolism Journal.2020; 44(2): 356.     CrossRef
• Diabetes and dementia – the two faces of Janus
  Athanasia Papazafiropoulou, Chris Koros, Andreas Melidonis , Stavros Antonopoulos
  Archives of Medical Science – Atherosclerotic Diseases.2020; 5(1): 186.     CrossRef